A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Denali Therapeutics Inc’s current trading price is 2.39% away from its 52-week high, while its distance from the 52-week low is 85.65%. The stock’s price range for this time frame has been between $14.56 and $26.40. The trading volume of the company’s shares in the Healthcare reached around 0.95 million for the day, which was evidently lower than the average daily volume of 1.1 million over the last three months.
Denali Therapeutics Inc’s stock market performance has been consistent. The 1-year high for the company’s stock was recorded at $26.40 on 09/11/24, with the lowest value being $14.56 on 04/25/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
Denali Therapeutics Inc (DNLI) has experienced a quarterly rise of 25.14% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 3.87B and boasts a workforce of 445 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 21.45, with a change in price of +10.18. Similarly, Denali Therapeutics Inc recorded 1,099,718 in trading volume during the last 100 days, posting a change of +61.33%.
How DNLI’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for DNLI stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.03.
DNLI Stock Stochastic Average
The raw stochastic average for Denali Therapeutics Inc over the last 50 days is presently at 99.58%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 99.34%. Further, the company’s Stochastic %K and %D values for the last 20 days were 96.81% and 91.90%, respectively.
DNLI Stock Price Performance Analysis
The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Until today this year the stock’s price performance recorded an increase of 25.96%. However, over the last six months, the performance has been weaker by 30.14%. The price of DNLI increased 20.03% over the last 30 days. And in the last five days, it has surged by 7.43%.
